MTFB has been the topic of several other reports. Northland Securities reaffirmed a buy rating on shares of Motif in a research report on Wednesday, February 21st. Northland Capital Partners reissued a buy rating on shares of Motif in a research report on Tuesday, March 20th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Motif has an average rating of Buy and an average price target of GBX 101.50 ($1.42).
Motif stock opened at GBX 35.25 ($0.49) on Tuesday. Motif has a one year low of GBX 23.50 ($0.33) and a one year high of GBX 51.75 ($0.73).
Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is Iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus.
Receive News & Ratings for Motif Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif and related companies with MarketBeat.com's FREE daily email newsletter.